Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The phase II/III GATSBY study (NCT01641939) showed that trastuzumab emtansine did not have an efficacy benefit over taxane in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric or gastroesophageal junction cancer. 31721447

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. 31620931

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Abnormalities in the expression levels of EGFR/HER2 are found in many different types of human cancer; therefore, the design of dual inhibitors of EGFR/HER2 is a recognized anti-cancer strategy. 31828486

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. 31087200

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE MCM2-LI was not shown to be predictive of disease recurrence during the median follow-up of 5.3 years but was shown to be useful to distinguish aggressive-type HER2-amplified breast carcinomas with high malignancy grade and hormone receptor negativity. 30358612

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE HER2 promotes the growth of cancer cells and makes them particularly aggressive. 31134823

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Human epidermal growth factor receptor 2 (HER2) is an attractive target for cancer therapy, although a large fraction of tumors that express HER2 may still resist first-line therapies. 31836485

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The human epidermal growth factor receptor 2 (HER2) plays an essential role in the tumorigenesis and tumor progression in cancer. 31829777

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE In summary, these findings demonstrated that circ-ERBB2 functions as an oncogene in GC and might be useful in developing promising therapies for this fatal malignancy. 30853181

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Prevalence and role of HER2 mutations in cancer. 30951733

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE VIR and CC-IR expressions are frequent in GC, biologically significant and even correlate with the HER2 status, opening avenues for novel putative therapeutic interventions in GC. 30989432

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Lobular cancer (incidence risk ratio [IRR], 1.29; 95% confidence interval [CI], 1.03-1.62), high grade and intermediate grade tumors (IRR, 1.90; 95% CI, 1.15-3.13 and IRR, 1.95; 95% CI, 1.18-3.22, respectively), high Ki67 proliferation index (IRR, 1.30; 95% CI, 1.02-1.66), and HER2 overexpression (IRR, 1.32; 95% CI, 1.12-1.55) were more likely to present with advanced disease, as were luminal B (HER2+) cancers (adjusted IRR [aIRR], 1.46; 95% CI, 1.10-1.95). 30691793

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy - Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 10b among patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. 31142325

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE This novel nanocarrier could potentially enable specific targeting to improve the efficacy of chemotherapy for HER2-positive cancer. 31213813

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Of 1,177 patients, 16% received guideline-discordant treatment, which was associated with nonwhite race, estrogen receptor/progesterone receptor negative, human epidermal growth receptor 2 (HER2) positive, and later-stage cancer. 30120157

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE In this study, we demonstrate that ethanol administration promotes STARD10 and ERBB2 expression that is significantly associated with increased cell malignancy and aggressiveness. 30611309

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE New studies suggested that HER2 expression is correlated with cancer stem cell (CSC) markers in breast cancer. 31211468

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE In order to meet the four-biopsy requirement for adequate HER2 assessment in >90% of cases, at least eight biopsies need to be taken, while 10 biopsies would be required for the 5-cancer biopsy threshold. 30592780

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Older patients with HER2-positive metastatic breast (HER2 + MBC) cancer are underrepresented in clinical trials. 31510955

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE HER2 testing in metastatic gastric or gastroesophageal junction cancer (mGC/mGEJC) is standard practice. 30826877

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Taken together, ERBB2 is required for the dysregulation of cancer-related genes, such as <i>MED24</i>, during lung tumor development. 31248101

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The diagnosis of HER2 positive cancer types such as breast- and gastric cancer is usually based on immunohistochemical HER2 staining of tumour tissue. 31455202

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The patients in the SNB group had a higher rate of estrogen receptor-positive and triple-negative breast cancers, but a lower rate of human epidermal growth factor receptor 2 (HER2)-positive cancer (p < 0.001). 31342364

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The importance of this system relies on the fact that the overexpression of HER2 protein is related with the poor prognosis breast cancers (HER2++ positives), while the TZM is a monoclonal antibody for the treatment of this cancer. 30832287

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Tumours often present characteristics of high malignancy and are hormone receptor negative/HER2 positive or triple negative. 31121525

2019